AI Engines For more Details: Perplexity Kagi Labs You
Hyperprolactinemia: Metergoline has been used to lower prolactin levels in conditions such as hyperprolactinemia, which can occur due to various factors including pituitary tumors, certain medications, and hypothalamic dysfunction. By blocking serotonin receptors, metergoline inhibits the release of prolactin from the pituitary gland.
Prolactin-Related Disorders: Elevated prolactin levels can lead to symptoms such as irregular menstrual periods, infertility, galactorrhea (production of breast milk in non-lactating individuals), and sexual dysfunction. Metergoline may help alleviate these symptoms by normalizing prolactin levels.
Migraine: Metergoline has also been investigated for its potential use in the treatment of migraines. Serotonin is believed to play a role in the pathophysiology of migraines, and metergoline's ability to block serotonin receptors may contribute to its effectiveness in preventing migraine attacks.
Psychiatric Disorders: Metergoline's mechanism of action on serotonin receptors suggests potential implications for the treatment of psychiatric disorders such as depression and anxiety. However, its use in these conditions is limited, and other medications with more established efficacy and safety profiles are typically preferred.
Gastrointestinal Disorders: Some research has suggested that metergoline may have effects on gastrointestinal motility and secretion, potentially making it useful in the treatment of conditions such as irritable bowel syndrome (IBS) and gastroparesis. However, further studies are needed to evaluate its efficacy and safety in these indications.
Side Effects: Common side effects associated with metergoline may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Additionally, it may cause dizziness, drowsiness, and headaches. Rare but potentially serious side effects may include serotonin syndrome, which is characterized by symptoms such as confusion, agitation, fever, sweating, and rapid heart rate.
Interactions: Metergoline may interact with other medications that affect serotonin levels or serotonin receptors, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and triptans used for migraine treatment. Combining metergoline with these medications may increase the risk of serotonin syndrome.
Pregnancy and Lactation: The safety of metergoline use during pregnancy and lactation has not been well established. It is generally not recommended for use in pregnant or breastfeeding women unless the potential benefits outweigh the risks and alternative treatments are not suitable.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.2 | 0.6 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.5 | 2.1 | 0.19 |
| Allergies | 5.6 | 3.1 | 0.81 |
| Allergy to milk products | 1.6 | 1 | 0.6 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 4.9 | 5.7 | -0.16 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.5 | 5.4 |
| Ankylosing spondylitis | 3.4 | 1.1 | 2.09 |
| Anorexia Nervosa | 1.3 | 2.7 | -1.08 |
| Antiphospholipid syndrome (APS) | 1 | 0.3 | 2.33 |
| Asthma | 4.7 | 3.1 | 0.52 |
| Atherosclerosis | 1.5 | 1.8 | -0.2 |
| Atrial fibrillation | 3.6 | 2.5 | 0.44 |
| Autism | 8.3 | 9.4 | -0.13 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 1.5 | 1.4 | 0.07 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.9 | 2.5 | -1.78 |
| Carcinoma | 3.5 | 2.3 | 0.52 |
| Celiac Disease | 2.4 | 3.7 | -0.54 |
| Cerebral Palsy | 1.6 | 1 | 0.6 |
| Chronic Fatigue Syndrome | 3.1 | 5.8 | -0.87 |
| Chronic Kidney Disease | 3.6 | 2.7 | 0.33 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 2 | -0.54 |
| Chronic Urticaria (Hives) | 0.8 | 1.5 | -0.88 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.8 | 1.6 | 0.75 |
| Colorectal Cancer | 5.4 | 2.2 | 1.45 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.1 | 2.8 | -1.55 |
| COVID-19 | 9.2 | 11.8 | -0.28 |
| Crohn's Disease | 6.5 | 6.1 | 0.07 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 1 | 1.1 | -0.1 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 9 | 8.9 | 0.01 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.3 | 1.9 | -0.46 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.4 | 2.2 | 0.09 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.4 | 1.6 | 1.13 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 3.7 | 0.3 |
| gallstone disease (gsd) | 2.3 | 1.4 | 0.64 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 1.2 | 0.42 |
| Generalized anxiety disorder | 2.1 | 2.2 | -0.05 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.9 | 0.8 | 1.37 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 2.1 | -1.33 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 3.2 | 1.5 | 1.13 |
| Heart Failure | 3.1 | 1.8 | 0.72 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1 | 0.3 | 2.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | 0 |
| hyperglycemia | 1.3 | 1.9 | -0.46 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.8 | 6.1 | -0.61 |
| Hypothyroidism | 0.3 | 1 | -2.33 |
| Hypoxia | 2.3 | 0.3 | 6.67 |
| IgA nephropathy (IgAN) | 1.6 | 4.6 | -1.87 |
| Inflammatory Bowel Disease | 7.2 | 8.7 | -0.21 |
| Insomnia | 2 | 2.9 | -0.45 |
| Intelligence | 0.8 | 0.6 | 0.33 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 6.5 | 5.3 | 0.23 |
| ischemic stroke | 2.3 | 1.1 | 1.09 |
| Liver Cirrhosis | 6.7 | 4.7 | 0.43 |
| Long COVID | 6.6 | 8.1 | -0.23 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.7 | 1.3 | -0.86 |
| Mast Cell Issues / mastitis | 0.4 | 0.6 | -0.5 |
| ME/CFS with IBS | 0.5 | 2 | -3 |
| ME/CFS without IBS | 1.2 | 1.9 | -0.58 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.8 | 1.63 |
| Metabolic Syndrome | 6.7 | 8.2 | -0.22 |
| Mood Disorders | 9 | 7.2 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 5.9 | 5.6 | 0.05 |
| Multiple system atrophy (MSA) | 1.4 | 0.4 | 2.5 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.4 | -10.33 |
| Neuropathy (all types) | 1 | 1.6 | -0.6 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.1 | 5.3 | -0.04 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 10.1 | 8.1 | 0.25 |
| obsessive-compulsive disorder | 4.5 | 4 | 0.13 |
| Osteoarthritis | 1.9 | 1.1 | 0.73 |
| Osteoporosis | 1.6 | 1.8 | -0.13 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.3 | 6.8 | 0.07 |
| Polycystic ovary syndrome | 5 | 2.6 | 0.92 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.4 | 2 | 0.2 |
| Psoriasis | 3.1 | 3.4 | -0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 4.5 | 0.56 |
| Rosacea | 0.4 | 0.7 | -0.75 |
| Schizophrenia | 6.5 | 3 | 1.17 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 2.6 | 2.6 | 0 |
| Sleep Apnea | 1.9 | 1.5 | 0.27 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 2.9 | 2.8 | 0.04 |
| Systemic Lupus Erythematosus | 3.7 | 2.1 | 0.76 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 4 | 4.1 | -0.02 |
| Type 2 Diabetes | 7.6 | 7.1 | 0.07 |
| Ulcerative colitis | 4.8 | 7.5 | -0.56 |
| Unhealthy Ageing | 4.8 | 2.7 | 0.78 |
| Vitiligo | 2 | 1.4 | 0.43 |
